Loading company
Avalo Therapeutics, Inc.
AVTX · Nasdaq · ·
Next earnings: November 5, 2026
$15.56+3.0%Sep 29 close
- 1M
- -20.6%
- 6M
- +11.7%
- 1Y
- +22.4%
- 5Y
- -99.8%
AVTX · Nasdaq · ·
Next earnings: November 5, 2026
$15.56+3.0%Sep 29 close
Avalo Therapeutics, Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toJun 30, 2024 | Change |
|---|---|---|---|
| Total Revenue | $59K | $0.00 | — |
| Profit | -$36.4M | -$20.8M | -75.09% |
| Profit per share | -$0.83 | -$1.92 | +56.77% |
| Free Cash Flow | -$15M | -$2.8M | -443.89% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“In the second quarter, we achieved the key objectives that positioned Avalo for its next phase of growth,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Avalo Therapeutics, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Avalo Therapeutics, Inc. has no earnings call transcript available.